1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Neurological Diseases Treatment Market
2.2. Global Neurological Diseases Treatment Market, By Drugs, 2023 (US$ Million)
2.3. Global Neurological Diseases Treatment Market, By Therapeutic, 2023 (US$ Million)
2.4. Global Neurological Diseases Treatment Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023

3. Neurological Diseases Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Neurological Diseases Treatment Market Vendors
3.2. Strategies Adopted by Neurological Diseases Treatment Market Vendors
3.3. Key Industry Strategies
4. Neurological Diseases Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Neurological Diseases Treatment Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Anticholinergic
5.3.2. Antiepileptic
5.3.3. Antipsychotic
5.3.4. Hypnotic & Sedative
5.3.5. Analgesics
5.3.6. Antihypertensive
5.3.7. Anticoagulants
5.3.8. Others

6. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Epilepsy
6.3.2. Alzheimer’s disease
6.3.3. Parkinson’s disease
6.3.4. Multiple Sclerosis
6.3.5. Cerebrovascular disease
6.3.6. Others


7. North America Neurological Diseases Treatment Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
7.3. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
7.4.Neurological Diseases Treatment Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
7.4.1.1.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
7.4.1.2.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
7.4.1.3.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)

8. UK and European Union Neurological Diseases Treatment Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
8.3. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
8.4.Neurological Diseases Treatment Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
8.4.1.1.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
8.4.1.2.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
8.4.1.3.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
8.4.1.4.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
8.4.1.5.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
8.4.1.6.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)

9. Asia Pacific Neurological Diseases Treatment Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
9.3. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
9.4.Neurological Diseases Treatment Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
9.4.1.1.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
9.4.1.2.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
9.4.1.3.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
9.4.1.4.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
9.4.1.5.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
9.4.1.6.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)

10. Latin America Neurological Diseases Treatment Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
10.3. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
10.4.Neurological Diseases Treatment Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
10.4.1.1.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
10.4.1.2.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
10.4.1.3.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)

11. Middle East and Africa Neurological Diseases Treatment Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
11.3. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
11.4.Neurological Diseases Treatment Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
11.4.1.1.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
11.4.1.2.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Neurological Diseases Treatment Market: By Drugs, 2022-2032, USD (Million)
11.4.1.3.2. Neurological Diseases Treatment Market: By Therapeutic, 2022-2032, USD (Million)

12. Company Profile
12.1. Novartis AG.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. GlaxoSmithKline plc.
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Merck & Co.
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Bayer AG.
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. AstraZeneca plc.
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Boehringer Ingelheim GmbH.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Teva Pharmaceutical Industries Ltd.
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. F. Hoffmann-La Roche AG.
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Zogenix, Inc.
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Eisai Co., Ltd.
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. AZTherapies, Inc.
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. Biogen, Inc.
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives
12.13. Intra-Cellular Therapies, Inc.
12.13.1. Company Overview
12.13.2. Financial Performance
12.13.3. Product Portfolio
12.13.4. Strategic Initiatives
12.14. Avid Radiopharmaceuticals.
12.14.1. Company Overview
12.14.2. Financial Performance
12.14.3. Product Portfolio
12.14.4. Strategic Initiatives
12.15. Avanir Pharmaceuticals.
12.15.1. Company Overview
12.15.2. Financial Performance
12.15.3. Product Portfolio
12.15.4. Strategic Initiatives
12.16. Johnson & Johnson (Janssen Pharmaceuticals).
12.16.1. Company Overview
12.16.2. Financial Performance
12.16.3. Product Portfolio
12.16.4. Strategic Initiatives
12.17. Sunovion Pharmaceuticals Inc.
12.17.1. Company Overview
12.17.2. Financial Performance
12.17.3. Product Portfolio
12.17.4. Strategic Initiatives
12.18. AbbVie, Inc.
12.18.1. Company Overview
12.18.2. Financial Performance
12.18.3. Product Portfolio
12.18.4. Strategic Initiatives
12.19. NeuroDerm Ltd.
12.19.1. Company Overview
12.19.2. Financial Performance
12.19.3. Product Portfolio
12.19.4. Strategic Initiatives
12.20. MedDay Pharmaceuticals SA.
12.20.1. Company Overview
12.20.2. Financial Performance
12.20.3. Product Portfolio
12.20.4. Strategic Initiatives